Video summary

Rhinosinusitis, Nasal Polyps and Asthma – What to do?

Main summary

Key takeaways

Educational

Main ideas, concepts, and lessons

1) Unified airway: why nasal polyps and asthma are linked

The video emphasizes the “unified airway” concept: the respiratory tract functions as a contiguous inflammatory organ from the nose to the terminal bronchi (and it even discusses links to the middle ear).

Key evidence presented includes:

  • Local allergen exposure affects distant tissue
    • Exposure in one part of the respiratory tract (e.g., lung or nose) can trigger eosinophilic inflammation in other regions the next day.
  • Shared gene-expression patterns
    • In asthma/recurrent wheeze, nasal and lower-airway gene expression show high similarity (reported: 91% shared).
  • Type 2 inflammation as a shared phenotype
    • Type 2 inflammation is described as dominant in both:
      • CRS with nasal polyps (CRS+NP) (reported: 87% type 2 inflammation)
      • Severe asthma (~85% type 2 inflammation)

2) Shared inflammatory mechanisms and polyp biology

The speaker outlines several biological concepts that may contribute to polyp formation:

  • Endogenous protease theory
    • Environmental triggers (example: dust mites) contain proteases that can damage the epithelial barrier.
    • Patients prone to disease may have a lower endogenous anti-protease balance, allowing deeper tissue involvement.
  • EMT-like process (epithelial-to-mesenchymal transition)
    • During healing, cells may shift into a “mesenchymal” state that can act as a temporary repair mechanism, but contributes to persistent dysfunction rather than healthy repopulation.
  • Fibrin-driven polyp growth
    • Polyps contain fibrin due to serum leakage from inflammation.
    • Under influence of eosinophils and macrophages, fibrin can become cross-linked, supporting persistence/growth.
    • Lab observation: applying a strong fibrinolytic to extracted polyps can shrink/dissolve them.

3) Clinical implications: recurrence risk and phenotype matters

  • Recurrence after surgery is common, so long-term management must focus on keeping inflammation suppressed to prevent regrowth.
  • Recurrence is more likely when there is eosinophilic involvement and specific comorbidities, especially:
    • Comorbid asthma
    • AERD (aspirin-exacerbated respiratory disease)
    • Fungal disease (mentioned)
  • A Japanese study (“Jezre” study) described stratifying patients by eosinophilic involvement (eosinophil counts, asthma, aspirin intolerance, imaging inflammation).
    • Those with a more severe eosinophilic component had a higher recurrence risk.

4) How asthma and sinus disease influence each other

  • The speaker notes frequent coexistence:
    • About 40% of people with CRS have comorbid asthma
    • About 20% among people with asthma have CRS
  • AERD escalation example
    • General asthmatics: aspirin sensitivity ~8%
    • Severe asthma: ~15%
    • Asthma + nasal polyps: AERD ~25–33%
  • Treating sinuses can improve lower-airway outcomes
    • Endoscopic sinus surgery can improve asthma-related outcomes such as:
      • quality of life
      • exacerbation rates
      • hospitalization
      • systemic steroid use
    • A chart-based study described a post-surgery effect:
      • patients with sinus disease developed asthma less often after sinus surgery
      • reported ~10-fold reduction in asthma-diagnosis rate (no-surgery vs post-surgery groups)
    • In AERD patients, after sinus surgery:
      • some temporarily lost aspirin reactivity (reported: 12 of 18 no longer reacted)
      • inflammatory mediators relevant to AERD decreased after repeat challenge

5) Etiology hypotheses connecting upper and lower airway disease

The speaker presents several plausible explanations (not definitive):

  • Not just allergy exposure
    • Example: cat allergen alone doesn’t explain it for most patients.
  • Possible contributors include:
    • systemic inflammation “limited” to airway (not fully satisfying as an explanation)
    • trafficking of eosinophils between compartments
    • barrier dysfunction and impaired barrier repair in both upper and lower airway
    • genetic predisposition toward an asthma-predominant vs CRS-predominant phenotype

6) Neurological/chemosensory contribution (sensory cell pathways)

A newer concept introduced is that sensory cells expressing “modified taste receptors” are present in the respiratory tract, including:

  • solitary chemosensory cells
  • brush cells
  • tufted cells

These cells can detect chemosensory changes (example: microbes/bacteria affecting glucose availability) and connect to neural pathways that may influence:

  • mucus production
  • ciliary beat frequency
  • other inflammatory/secretory responses

Treatment content and methodologies (structured bullet points)

A) Topical (upper-airway) therapy and its effect on asthma

  • Nasal/intranasal corticosteroids (topical)
    • Presented as a first-line important therapy for CRS with nasal polyps.
    • Guideline summaries:
      • IAR (states): intranasal steroids outperform placebo; twice daily may help more than once daily (small effect).
      • GRADE (recent): recommends intranasal corticosteroids vs none, but evidence certainty described as low/conditional.
    • Harm described as minimal in the guideline overview.
  • Evidence for topical nasal treatment reducing asthma
    • Overall evidence is limited.
    • One double-blind placebo-controlled trial (~400 adults/children):
      • uncontrolled asthma + CRS treated with mometasone intranasal corticosteroids
      • improved asthma symptoms, but no major change in FEV1 or asthma quality of life.
  • Sinus rinses / steroid delivery systems / stents
    • As of the talk, the speaker states there is no solid evidence clearly showing improvement in asthma outcomes.

B) Aspirin therapy after desensitization (AERD patients)

The talk distinguishes:

  • Office desensitization
  • ongoing aspirin therapy after desensitization

Evidence summarized:

  • multiple randomized controlled trials + meta-analysis:
    • strong effect on polyp growth rate
    • secondary improvement in sinus symptoms
    • no regression of established/fully grown polyps

Clinical implications:

  • patients “full of polyps” generally need surgery first, not aspirin therapy as a primary approach.
  • asthma effects are described as secondary (not the main driver of unstable/difficult-to-control asthma).

Side effects:

  • dose-dependent; GI toxicity
  • ~15% may not tolerate aspirin

C) Surgery (endoscopic sinus surgery) and disease modification

The talk frames how surgery can change outcomes:

  • Surgery is important for upper-airway control and can also modify lower-airway disease, including asthma outcomes.
  • Considerations mentioned:
    • First-step standard surgery:
      • debulking polyps
      • ventilating/maxillary sinus access
      • opening ethmoid air cells
    • Earlier recurrence can be a red flag for considering biologic therapy.
    • Later recurrence may warrant more extensive surgery, including frontal sinus procedures (e.g., “frontal drill out” / Draf III).
    • COS (completeness of surgery index) concept:
      • if recurrence occurs after “complete enough” surgery, it may suggest the need for medical therapy rather than more surgery.
    • Encourage second opinions because surgical approaches can vary.

D) Biologics: how they are used for CRS with NP and comorbid asthma

Method for selecting candidates (as described)

Biologics are considered in CRS with NP, especially when:

  • there is recurrence after surgery
  • there is comorbid asthma (explicitly stated as supportive)

The speaker stresses a management structure:

  • For CRS with NP + asthma + AERD (or suspected AERD), involve an asthma specialist, because biologic strategy becomes more complex.

Evidence structure / monitoring approach presented

Key principles:

  • use comorbid asthma status to guide expectations of response (subgroup analysis described for multiple drugs)
  • monitor upper-airway and asthma outcomes (e.g., SNOT-22 for sinuses; FEV1/ACT for asthma)

Biologics discussed (upper and lower airway focus)

  • The speaker notes four FDA-approved biologics for both asthma and CRS with nasal polyps.
  • Additional note:
    • Benralizumab was mentioned as not FDA-approved for CRS with NP and was not pursued for that indication (per speaker).

Drug-specific takeaways:

  • Dupilumab (Dupixent)
    • sinus trials (SINUS-24/SINUS-52) included participants with comorbid asthma
    • among polyp populations with comorbid asthma:
      • improved snot/anatomical outcomes
      • some improvements in FEV1 and asthma symptoms
  • Omalizumab
    • included asthma subgroups; analyses suggest asthma status can help stratify response (AERD may do better than asthma-only in some comparisons)
  • Mepolizumab
    • subgroups suggest patients with comorbid asthma may show polyp-score improvement (positioned as predictive)
  • Tezepelumab (newest for CRS with NP)
    • approval for CRS with NP described as recent
    • subgroup differences for AERD/asthma noted as less pronounced than for some other biologics; still overall favored active drug over placebo
  • “Depokimab” (not yet marketed at the time of talk)
    • IL-5 pathway targeting with long half-life
    • study suggests asthma presence may correlate with better response

Concepts introduced:

  • Remission goals
    • “remission” in asthma extends to sinus disease
    • “cure” defined as sustained remission (example: 5 years off treatment)
  • “Super responder”
    • patients with near-complete control in both asthma and sinus disease (including minimal/near-zero symptom scores like SNOT-22 thresholds mentioned)

E) Unified-treatment goals for patients with both diseases

The speaker highlights the clinical dilemma: patients often need one regimen that treats both upper and lower disease.

Examples presented:

  • Small European study (~20 severe asthma patients with poorly controlled polyps on other biologics):
    • switching to dupilumab improved sinus outcomes for all but one (that one had asthma worsening)
  • Tezepelumab registry study:
    • improved asthma and improved SNOT-22 sinus symptom score
  • “Super responders” study:
    • identified a subset meeting stringent criteria in both airways
    • included exploratory gene expression signals to predict who achieves super-response

F) What clinicians should do in practice (workflow recommendations)

A practical approach is proposed to avoid missing the dominant driver:

  • Evaluate both upper and lower airway disease at each visit using objective measures.
  • Example metrics emphasized:
    • SNOT-22 (sinus symptoms)
    • ACT (asthma control)
    • AirQ (mentioned as part of clinic testing)

Key lesson:

  • patients may talk only about asthma or only about sinuses—clinicians should still check both domains
    • e.g., if SNOT-22 is high, sinus symptoms are significant even if the patient didn’t raise them.

Conclusion / forward-looking themes

  • Upper and lower airway diseases share mechanisms and often behave as a single inflammatory system.
  • Biologics and surgery can both improve outcomes in both compartments, but:
    • long-term comparative data (biologic vs surgery) remain limited, especially beyond early time points.
  • Future needs:
    • better biomarkers to identify type 2-driven disease early
    • better evidence on sequencing/combining therapy (surgery + biologics)
    • better definitions and targets for simultaneous remission (upper + lower airway)

Speakers / sources featured

Speakers

  • Ruthie Marker — Education Program Manager, Allergy Asthma Network (host/moderator intro and webinar logistics)
  • Dr. Andrew White — Board-certified allergist and immunologist, Scripps Clinic (main presenter)

Organizations / program sources mentioned

  • Allergy Asthma Network (webinar host)
  • American College of Allergy, Asthma, and Immunology (ACAAI) (CME/credits collaboration)

Named researchers / study groups / study sources referenced

  • 2000 unified airway study (grass-allergic patients; bronchoscopy + allergen instillation; eosinophils in nose/lung)
  • Whitney Stevens and Northwestern (inflammation profiling: type 1/type 2/type 3; CRS with nasal polyps type 2 percentage noted)
  • Japanese “Jezre” study (CRS recurrence stratification by eosinophilic involvement)
  • Raj Synwani and colleagues (sinus disease onset → sinus surgery; asthma diagnosis development halted/modified after surgery)
  • AERD sinus surgery challenge-response study (post-surgery aspirin reactivity changes)
  • Meta-analysis by Oman (aspirin therapy effects across studies, including polyps/symptoms)
  • SINUS-24 and SINUS-52 (dupilumab sinus trials; comorbid asthma subgroup discussion)
  • Trials referenced for omalizumab, mepolizumab, tezepelumab (and a non-market drug depokimab)
  • European “super responder” study (complete control of asthma + CRS with NP; gene expression exploration)
  • European switch study (dupilumab used after inadequate polyp control on other biologics)
  • Studies about readmission risk with comorbid non-allergic rhinitis in asthma/COPD (as described by the speaker)

Other named terms (not necessarily “sources” but explicitly mentioned)

Unified airway; tufted/brush/solitary chemosensory cells; COS (completeness of surgery index); SNOT-22; ACT; AirQ

Original video